Jaimie Barr

Ms. Jaimie Barr


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
NBNicolaas I. Bohnen
Nicolaas I. Bohnen
JBJaimie Barr
Jaimie Barr
RVRobert Vangel
Robert Vangel
SRStiven Roytman
Stiven Roytman
RPRebecca Paalanen
Rebecca Paalanen
PKPrabesh Kanel
Prabesh Kanel
Flumazenil is an allosteric modulator of the γ-aminobutyric acid-A receptor (GABAAR) benzodiazepine binding site that could normalize neuronal signaling and improve motor impairments in Parkinson’s disease (PD). Little is known about how regional GABAAR availability affects motor symptoms. We investigated the relationship between regional availability of GABAAR benzodiazepine binding sites and motor impairments in PD. Methods: A total of 11 Patients with PD (males; mean age 69.0 ± 4.6 years; Hoehn and Yahr stages 2–3) underwent [11C]flumazenil GABAAR benzodiazepine binding site and [11C]dihydrotetrabenazine vesicular monoamine transporter type-2 (VMAT2) PET imaging and clinical assessment. Stepwise regression analysis was used to predict regional cerebral correlates of the four cardinal UPDRS motor scores using cortical, striatal, thalamic, and cerebellar flumazenil binding estimates. Thalamic GABAAR availability was selectively associated with axial motor scores (R2 = 0.55, F = 11.0, β = −6.4, p = 0.0009). Multi-ligand analysis demonstrated significant axial motor predictor effects by both thalamic GABAAR availability (R2 = 0.47, β = −5.2, F = 7.2, p = 0.028) and striatal VMAT2 binding (R2 = 0.30, β = −3.9, F = 9.1, p = 0.019; total model: R2 = 0.77, F = 11.9, p = 0.0056). Post hoc analysis demonstrated that thalamic [11C]methyl-4-piperidinyl propionate cholinesterase PET and K1 flow delivery findings were not significant confounders. Findings suggest that reduced thalamic GABAAR availability correlates with worsened axial motor impairments in PD, independent of nigrostriatal degeneration. These findings may augur novel non-dopaminergic approaches to treating axial motor impairments in PD.


1 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
TWTravis P. Wigstrom
Travis P. Wigstrom
SRStiven Roytman
Stiven Roytman
JBJeff Bohnen
Jeff Bohnen
RPRebecca R. Paalanen
Rebecca R. Paalanen
AGAlexis Griggs
Alexis Griggs
NBNicolaas I. Bohnen
Nicolaas I. Bohnen
Background With Bipolar Disorder (BD) having a lifetime prevalence of 4.4% and a significant portion of patients being chronically burdened by symptoms, there has been an increased focus on uncovering new targets for intervention in BD. One area that has shown early promise is the mitochondrial hypothesis, with supporting evidence in the form of mtDNA copy number, SNPs, ETC complex activity in peripheral cells, postmortem analyses of ETC function, and iPSC-derived biomarkers, among others. Despite this compelling evidence, at the time of this publication no studies have utilized PET imaging to assess mitochondrial function in the setting of BD. Case Presentation Our participant is a 58 year old male with a past medical history notable for alcohol use disorder and bipolar disorder (unspecified type) who, while enrolled as a control for a separate trial, underwent PET imaging with the mitochondrial complex 1 PET ligand 18F-BCPP-EF. Those images were compared to normal controls which demonstrated significant overlap between areas of dysfunction identified with the 18F-BCPP-EF PET ligand and areas of dysfunction previously identified in the setting of BD with fMRI techniques. That overlap was seen in both affective and cognitive circuits, with mitochondrial dysfunction in the fronto-limbic, ventral affective, and dorsal cognitive circuits showing particularly significant differences. Conclusions Despite mounting evidence implicating mitochondria in BD, this study represents the first PET imaging study to investigate this mechanistic connection. There were key limitations in the form of comorbid alcohol use disorder, limited statistical power inherent to a case study, no sex matched controls, and the absence of a comprehensive psychiatric history. However, even with these limitations in mind, the significant overlap between areas of dysfunction previously demonstrated on fMRI and this 18F-BCPP-EF PET ligand imaging provides compelling preliminary evidence that strengthens the mechanistic link between mitochondrial dysfunction and Bipolar Disorder and warrants further investigation.